Thanks for the link.
CHM's AML trial is at MDA Texas and if I recall it correctly the current CHM 1101 ph1b got them as one trial site as well.
And all that plus the other platforms for AUD 5m. The ASX " really got an understanding" of valuing CHM.
The re-rate will come at some stage, fortunately I got the time to wait. One of those rare opportunities to lay a foundation for a huge windfall if the data turn into approved treatments. Not to mention the benefits for cancer sufferers.
GLTA
Ann: Positive in vitro data for CHM 1301 CAR NK cells-supplement, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |